116913-58-7

Basic information

• Product Name: 2-(methoxycarbonyl)-5-methoxy-3-methylbenzoic acid
• Synonyms: 2-(methoxycarbonyl)-5-methoxy-3-methylbenzoic acid
• CAS NO: 116913-58-7
• Molecular Weight: 224.213
• Mol File: 116913-58-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(methoxycarbonyl)-5-methoxy-3-methylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(methoxycarbonyl)-5-methoxy-3-methylbenzoic acid(116913-58-7)
• EPA Substance Registry System: 2-(methoxycarbonyl)-5-methoxy-3-methylbenzoic acid(116913-58-7)

Safety Data

• Hazardous Substances Data: 116913-58-7(Hazardous Substances Data)

Usage

Type of compound

Derivative of benzoic acid

Substituent groups

Methoxycarbonyl at the 2 position, methoxy at the 5 position, and methyl at the 3 position

Usage

Organic synthesis, medicinal chemistry

Pharmacological properties

Anti-inflammatory, analgesic

Applications

Production of pharmaceuticals, agrochemicals

Additional potential

Antioxidant, therapeutic effects in various medical applications

Upstream product

• 108298-35-7 dimethyl 5-methoxy-3-methylbenzene-1,2-dioate 

Downstream Products

• 118718-71-1 Methyl 2-amino-4-methoxy-6-methylbenzoate 
• 118718-72-2 Methyl 2-(3-isopropylureido)-4-methoxy-6-methylbenzoate 
• 116913-61-2 Methyl 2-ethoxycarbonylamino-4-methoxy-6-methylbenzoate 
• 1015443-56-7 methyl 4-methoxy-2-(methoxycarbonylamino)-6-methylbenzoate 
• 118730-25-9 2-Isocyanato-4-methoxy-6-methyl-benzoic acid methyl ester 

Relevant articles and documents

Studies on Antibiotics Active against Resistant Bacteria. Total Synthesis of MRSA-Active Tetarimycin A and Its Analogues

Making use of the Hauser-Kraus annulation as a key step, the first total synthesis of tetarimycin A has been accomplished in a highly convergent and operationally simple manner. Preliminary SAR not only validated that tetarimycin A exhibited potent activi

SUBSTITUTED DIHYDRO-ISOINDOLONES USEFUL IN TREATING KINASE DISORDERS

The present invention is directed to novel substituted dihydro-isoindolone compounds of formula (I): and forms thereof, wherein Ring A, X3, R1, R2, R3, R4 and R6 are as herein defined, and their synthesis and use as protein kinase inhibitors and interactions thereof.